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Enhanced topical delivery of dexamethasone
by β-cyclodextrin decorated thermoresponsive
nanogels†
M. Giulbudagian,a S. Hönzke,b J. Bergueiro,a D. Işık,a F. Schumacher,c,f S. Saeidpour,d
S. B. Lohan,e M. C. Meinke,e C. Teutloﬀ,d M. Schäfer-Korting,b G. Yealland,b
B. Kleuser,c S. Hedtrichb and M. Calderón *a
Highly hydrophilic, responsive nanogels are attractive as potential systems for the topical delivery of
bioactives encapsulated in their three-dimensional polymeric scaﬀold. Yet, these drug carrier systems
suﬀer from drawbacks for eﬃcient delivery of hydrophobic drugs. Addressing this, β-cyclodextrin (βCD)
could be successfully introduced into the drug carrier systems by exploiting its unique aﬃnity toward
dexamethasone (DXM) as well as its role as topical penetration enhancer. The properties of βCD could be
combined with those of thermoresponsive nanogels (tNGs) based on dendritic polyglycerol (dPG) as a
crosslinker and linear thermoresponsive polyglycerol (tPG) inducing responsiveness to temperature
changes. Electron paramagnetic resonance (EPR) studies localized the drug within the hydrophobic cavity
of βCD by diﬀerences in its mobility and environmental polarity. In fact, the fabricated carriers combining
a particulate delivery system with a conventional penetration enhancer, resulted in an eﬃcient delivery of
DXM to the epidermis and the dermis of human skin ex vivo (enhancement compared to commercial
DXM cream: ∼2.5 fold in epidermis, ∼30 fold in dermis). Furthermore, DXM encapsulated in βCD tNGs
applied to skin equivalents downregulated the expression of proinﬂammatory thymic stromal lympho-
poietin (TSLP) and outperformed a commercially available DXM cream.
Introduction
The topical administration of drugs is the route of choice for
the treatment of many inflammatory skin diseases. Likewise, it
serves as a powerful tool for the non-invasive systemic appli-
cation of drugs subjected to strong hepatic first-pass eﬀect
and/or short duration of action following oral intake.1 Yet, the
challenge to overcome the physical and biological barriers of
the skin demands the use of advanced formulations, e.g. by
the use of drug carriers or penetration enhancers.2 To over-
come that, a variety of carrier systems in the nanometric size
have been developed in the recent years.3 The encapsulation
capabilities of both hydrophilic and hydrophobic drugs in
their three dimensional scaﬀold have been investigated to
meet the pharmacokinetics needs in specific pathological
condition.4–6 Polymeric carrier systems can be highly eﬀective
for topical drug delivery, increasing the eﬀective drug concen-
tration in the viable tissue.2,3,7 Most studies report on the
accumulation of the carriers in the outermost physical skin
barrier, the stratum corneum (SC), while enabling the pene-
tration of the encapsulated moiety into viable skin layers, the
site of action.8
Enhanced penetration of drugs into the skin can also be
achieved by using various chemical penetration enhancers. For
instance, fatty acids, alcohols, and sulfoxides enhance the per-
cutaneous absorption of drugs.9 Nevertheless, out of a tested
library of existing penetration enhancers, 99.50% were elimi-
nated due to caused irritancy or low potency.10 Cyclodextrins
(CDs) are a group of cutaneous penetration enhancers,
however not comparable with other chemical enhancers in
their mode of action, i.e. penetration into the barrier.11,12 CDs
are interesting building blocks for diﬀerent drug delivery
systems because of their biocompatibility and a unique ability
to build host–guest complexes with a variety of especially
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hydrophobic biologically active molecules.13,14 Rather than
direct interaction with the SC components and the pertur-
bation of their organization, CDs enhance topical delivery of
drugs by increasing the solubilization and the partition of the
drug in the skin.15,16 Other studies showed the ability of βCDs
to extract SC lipids, resulting in enhanced absorption of hydro-
philic as well as hydrophobic drugs, independent of inclusion
complex formation.17,18 Importantly, excellent biocompatibility
was demonstrated on various studies for CDs after topical
application.19–22 Dexamethasone (DXM) is one of the most fre-
quently used corticosteroid for topical application. Its
inclusion complex with βCD has been applied for the ocular
delivery of the drug as well as a topical ointment formulation
known as Glymesason.23,24 While such complexation could
substantially improve DXM absorption, βCD itself was found
to penetrate into the viable tissue in particular into barrier dis-
rupted models.25 Hence, the integration of βCD properties
with polymeric particulate systems could provide an advan-
tageous platform for cutaneous drug delivery.
Nanogels are three-dimensional scaﬀolds of polymeric
building blocks which form nanosized particles due to chemi-
cal bonds and/or physical interaction.26 Their unique behavior
to absorb large amounts of water in their polymeric network
in aqueous media enables also the ability to encapsulate bio-
logically active molecules, providing a protective environment
from degradation or rapid clearance.27–30 Thermoresponsive
nanogels (tNGs) in particular are attractive carriers for the
topical delivery of drugs due to their unique ability to undergo
a transition from highly hydrophilic to hydrophobic state upon
a temperature trigger using the thermal gradient of the skin
(32 °C–37 °C).31–33 Their ability to hydrate the SC by repealing
the inner water molecules, resulted in the perturbation of the
lipid and protein organization.34 While diﬀerent model mole-
cules and therapeutic biomacromolecules could be delivered
into the viable tissue with the aid of tNGs, the carriers
remained mainly accumulated in the SC.34,35 Yet, tNGs, as
other hydrophilic carrier systems suﬀer from low encapsula-
tion capacities and ineﬃcient delivery of highly hydrophobic
drugs.
Herein we describe a modular approach for the surface
modification of tNGs, simultaneously inducing skin pene-
tration enhancement and aﬃnity towards hydrophobic drugs.
The multifunctional surface of dendritic polyglycerol (dPG)
enabled its function as a macro-crosslinker between linear
thermoresponsive polyglycerol (tPG) units. These carriers were
previously proven to be highly tolerated by primary normal
human keratinocytes in terms of cell viability, genotoxicity,
reactive oxygen species formation, as well as eye irritancy.36,37
The developed synthetic pathway served as a convenient plat-
form for tNG surface decoration, enabling the accessibility
towards βCD grafting or fluorescent labeling of the carriers.
Electron paramagnetic resonance (EPR) studies were employed
to investigate the localization and possible encapsulation of
DXM within the βCD hydrophobic cavity. The βCD decorated
tNGs were examined for their ability to deliver DXM into the
viable epidermis and dermis of human skin ex vivo, compared
to a commercially available DXM cream. Human-based skin
equivalents emulating clinical characteristics of atopic derma-
titis (AD) due to a knockdown of the filaggrin gene (FLG−) and
exposure to Th2 cytokines IL-4 and IL-13,38 served for the
investigation of DXM eﬀect. The suppression of thymic
stromal lymphopoietin (TSLP), a key factor in AD treatment,
was followed upon the application of the developed carriers.
Materials and methods
The chemicals were purchased from Acros Organics, Alfa
Aesar, Roth, Sigma-Aldrich, Deutero GmbH, and used as
received. DXM-d4 was purchased from C/D/N Isotopes
(Quebec, Canada). For the column chromatography silica gel
60 from Merck-Schuchardt® (40–60 nm, 230–400 mesh) was
used. The thin layer chromatography (TLC) plates were pur-
chased from Merck® (silica gel 60, fluorescence indicator
F254, thickness 0.25 mm). Water used for the synthesis was
obtained from a Millipore water purification system. Dendritic
polyglycerol (dPG) with average Mw of 10 kDa (PDI = 1.27) was
purchased from Nanopartica GmbH (Berlin, Germany). The
amine functionalization of dPG was performed by a previously
reported protocol39 while the degrees of functionalization for
dPG-BCN15% are given as the percentage of the total hydroxyl
groups of the dPG (∼ 135 hydroxyl groups for 10 kDa dPG).
Glycidyl methyl ether (GME) (85%) and ethyl glycidyl ether
(EGE) (98%; both TCI Europe, Eschborn, Germany) were dried
over CaH2, distilled, and stored over molecular sieves (5 Å).
The crosslinking reagent (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-
ylmethyl (4-nitrophenyl) carbonate (BCN) was purchased from
Synaﬃx (AE Oss, Netherlands).40 The synthesis and
functionalization of linear thermoresponsive polymers was
performed according to a slightly modified procedure as
already reported.41,42
All NMR spectra were recorded on a JEOL ECX400 spectro-
meter operating at 400 MHz and JEOL ECP500 spectrometer
operating at 500 MHz at concentrations of 5–20 mg mL−1. All
data were analyzed using MestReNova software. DLS measure-
ments were performed using a Malvern Zetasizer Nano ZS
ZEN3600. IR spectra were recorded with a Nicolet iS10 FT-IR
spectrometer.
Cloud point temperature (Tcp) determination by turbidimetry
measurement
The Tcp were measured on a Lambda 950 UV/Vis/NIR spectro-
meter, PerkinElmer Life and Analytical Sciences (Connecticut,
USA) equipped with a temperature-controlled, six-position
sample holder. Buﬀer phosphate pH 7.4 nanogel solutions
were heated at 0.2 °C min−1 while monitoring both the trans-
mission at 500 nm (1 cm path length) and the solution temp-
erature (from 18 to 55 °C), as determined by the internal temp-
erature probe. The Tcp of each nanogel was defined as the
temperature at the inflection point of the normalised trans-
mission curves.
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Atomic force microscopy (AFM)
AFM measurements were recorded by a tapping mode with a
MultiMode 8 AFM equipped with a Nanoscope V controller
from Veeco Instruments, Santa Barbara, California. The data
was analyzed using NanoScope Analysis 1.3 software and stat-
istical analysis were performed in a 10 µm × 10 µm image. The
tNGs aqueous solutions (2.5 mg mL−1) were air dried on a
Mica sheet. Samples were analyzed by Nano World tips, Soft
Tapping Mode (SNK-10), with a resonance frequency of 56–75
kHz and a force constant of 0.24 N m−1.
Transmission electron microscopy (TEM)
TEM samples were prepared by applying a droplet (5 μL) of the
sample solution (10 mg mL−1 in Milli-Q water) on a hydrophi-
lised (60 s low discharging at 8 W using a BALTEC MED 020
device) carbon-coated copper grid (400 meshes, Quantifoil
Micro Tools GmbH, Großlöbichau, Germany) for 60 s. The
supernatant fluid was removed by blotting with filter paper.
Then a droplet (5 μL) of 1% (w/v) uranyl acetate solution was
applied and kept for another 60 s. The excess contrasting
material was removed by means of filter paper and the sample
was allowed to dry in air. The measurements were carried out
using the TEM mode of a Hitachi Scanning Electron
Microscope (SU8030, Hitachi High-Technologies Corporation,
Tokyo, Japan) (20 kV) at diﬀerent magnifications.
mono-6-(p-Toluenesulfonyl)-6-oxy-βCD (βCD-Ts)
In a 1 L three-necked round bottom flask 25 g of βCD
(22 mmol, 1 eq.) were dried under vacuum for 1 h while 8.4 g
of p-toluenesulfonyl chloride (44 mmol, 2 eq.) were dissolved
in 30 mL of freshly opened dry pyridine. Then 400 mL of dry
pyridine was added to the βCD under dry conditions. The
p-toluenesulfonyl chloride was added dropwise to the βCD at
0 °C under vigorous stirring. After the addition the reaction
mixture was stirred at 0 °C for 1 h, temperature allowed to
raise to room temperature (r.t.), and kept overnight under con-
tinuously stirring. Intermittently the progress of the reaction
was monitored with TLC (1-butanol/ethanol/water = 5/4/3;
stained by p-anisaldehyde). The solution was concentrated to
half of the volume and precipitated using 600 mL of acetone
while vigorously stirring. The crude product was then recrystal-
lized in water three times and lyophilized to obtain 12.6 g
(44.4%) of βCD-Ts as a white solid. 1H-NMR (400 MHz,
dimethyl sulfoxide (DMSO)-d6): δ = 7.75 (d, J = 8.3 Hz, 2H, Ar–H̲),
7.43 (d, J = 8.3 Hz, 2H, Ar–H ̲), 5.98–5.55 (m, 14H, C2,3–OH ̲),
4.97–4.67 (m, 7H, C1–H ̲), 4.55–4.16 (m, 6H, C6–OH ̲), 3.87–3.43
(m, 28H, C2,3,4,5–H ̲), 3.47–3.15 (m, 14H, –C6–H ̲2; overlap with
HDO), 2.43 ppm (s, 3H, –CH̲3).
43,44
mono-6-Azido-6-deoxy-βCD (βCD-N3)
In a 100 mL round flask 650 mg of mono-6-(p-toluenesulfonyl)-
6-oxy-βCD (0.503 mmol, 1 eq.) and 653.3 mg of sodium azide
(10.1 mmol, 20 eq.) were dissolved in 50 mL of deionized water
and refluxed at 90 °C overnight. The crude product was then
precipitated and washed using 100 mL of acetone to result in
574.3 mg (98%) of βCD-N3 as a white solid. 1H-NMR (400 MHz,
DMSO-d6): δ = 5.75 (s, 14H, C2,3–OH ̲), 4.94–4.76 (m, 7H, C1–H ̲),
4.63–4.37 (m, 6H, C6–OH ̲), 3.81–3.50 (m, 28H, C2,3,4,5–H ̲),
3.47–3.15 ppm (m, 14H, –C6–H̲2; overlap with HDO); IR (ATR): ν˜ =
3301 (O–H str & brd), 2923 (C–H med), 2102 (–N3 med & shp),
1152 (C–O–C med) 1021 (C–O str & shp), 996 cm−1 (C–O str).44,45
Functionalization of dPG with βCD (dPG-BCN-βCD)
The functionalization of dPG with BCN units was performed
as previously reported.42 For βCD conjugation, 20 mg of
dPG-BCN(15%) (54 µmol BCN-groups, 1 eq.) were dissolved in
3 mL of dimethylformamide (DMF). To this solution a:
3.14 mg and b: 9.4 mg of βCD-N3 (a: 0.54 µmol, 0.01 eq. for 1%
functionalization; b: 1.6 µmol, 0.03 eq. for 3% of functionali-
zation) were added dissolved in 1 mL of DMF. The reaction
mixture was stirred overnight at r.t. The crude product was
then dialyzed against methanol for 1 d. 1H-NMR (500 MHz,
CH3OD) δ = 5.72 (s, 14H, C2,3–OH ̲), 4.92–4.38 (m, 13H, C1–H ̲;
C6–OH ̲), 4.13–3.98 (m, 2H, C7–H ̲2), 3.78–3.21 (m, 300H, dPG/
CD backbone), 2.30–2.00 (m, 4H, C12,15–H ̲2), 1.36–1.20 (m, 4H,
C11,16–H ̲2), 1.15–0.78 ppm (m, 3H, cyclopropyl ring).
Synthesis of thermoresponsive nanogels (tNG_tPG)
For tPG based nanogels (tNG_tPG) 20 mL of Milli-Q water in a
glass vial were heated in an oil bath to 45 °C. In parallel azide
functionalized tPG (tPG-(N3)2) (15 mg) and dPG-(BCN)10%
(5 mg) were dissolved separately in DMF (0.5 mL). The solu-
tions were cooled down in an ice bath to 0 °C. Both solutions
were mixed together under cooling and injected via a syringe
into the water at 45 °C. After keeping the reaction at 45 °C for
6 h the unreacted alkynes were quenched with azidopropanol
and let to react for another 2 h. For βCD grafting, the reaction
was quenched with β-CD-N3. For fluorescent labelling, the
quenching was performed with indodicarbocyanine azide
(IDCC-N3). Following, the nanogel solution was dialyzed
(regenerated cellulose, molecular weight cut oﬀ (MWCO)
50 kDa) against water for 1 d, concentrated and purified by a
Sephacryl S-100 column.
βCD grafted thermo-responsive nanogels (tNG_tPG_βCD)
In a 5 mL glass vial 5.6 mg of dPG-BCN(15%) (11.35 µmol BCN-
groups, 3 eq.) (or alternatively dPG-BCN-βCD) were dissolved in
0.5 mL of DMF. Separately, a solution of 9.5 mg of tPG-(N3)2
(1.9 µmol) in 0.5 mL of DMF was prepared. After cooling both
solutions to 0 °C, they were mixed for half a minute and
injected into 20 mL of MilliQ water at 45 °C. The reaction
mixture was stirred overnight, quenched with 35 mg of βCD-N3
(34 µmol, 3 eq.) while stirring for an additional hour, and puri-
fied by dialysis against water for 3 d: 1H-NMR (700 MHz, DMF-
d7) δ = 3.70–3.49 (m, 412H, dPG, tPG, and βCD backbone), 3.35
(s, 3H, –OCH̲3), 1.20–1.14 ppm (m, 3H, –OCH2C̲H3).
DXM loading and release
For loading of dexamethasone (DXM), 5 mg of DXM were
added to tNG_tPG or tNG_tPG_βCD (10 mg) in 2 mL of MilliQ
water at 37 °C. The nanogels were let to swell by cooling the
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dispersions in an ice bath, followed by sonication in a water
bath for 30 min. The dispersions were stirred overnight at
25 °C and the insolubilized fraction was filtered oﬀ with a
0.45 µm regenerated cellulose syringe filter. Following, 100 µL
of the encapsulated fraction were lyophilized for determi-
nation of the total concentration. The loading capacity was
determined by LC-MS/MS, as described previously.36 The
nanogels with the encapsulated drugs were stored at 4 °C. For
the in vitro release studies, the tNGs with the encapsulated
drug were placed in a centrifugal filtering device Vivaspin
300 kDa and incubated at 25 °C or 37 °C. At certain time inter-
vals, the incubated solutions were centrifuged (5 min,
6000 rpm) and replaced with a fresh PBS buﬀer. The filtrate
was lyophilized, dissolved in acetonitrile and analyzed by
UV-Vis (absorbance read at 241 nm).
Analysis of the association of DXM with the cavities of βCD by
electron paramagnetic resonance (EPR) spectroscopy
To study the localization of DXM to the cavities of βCD, dual
frequency EPR spectroscopy was performed. For this purpose,
the various tNGs (tNG_tPG and tNG_tPG_βCD) were loaded
with DXM which was labelled by the spin marker 3-carboxy-
2,2,5,5-tetramethyl-1-pyrrolidinyloxy (PCA).46–48 DXM-PCA in
water (log P = 1.89), in DMSO and an aqueous solution of βCD
served as references. A X-band EPR spectrometer (ν = 9.5 GHz,
Magnettech MiniScope MS5000, Berlin, Germany) with the fol-
lowing parameter settings was used: microwave power 10 mW,
sweep width 20 mT, sweep time 940 s, modulation frequency
100 kHz, modulation amplitude 0.1 mT. The temperature was
adjusted by a TC H014 temperature controller (Magnettech
GmbH). The particle solutions were measured in quartz capil-
laries (QSIL GmbH, Langewiesen, Germany) sized 2 mm/
1.0 mm outer/inner diameters (OD/ID).
The nitrogen hyperfine coupling and the Zeeman inter-
action (g- and A-matrix) of the unpaired electron on a nitroxide
are highly sensitive parameters for the surrounding micro-
environment properties.49,50 To investigate these magnetic
parameters for DXM-PCA loaded to diﬀerent tNGs and in
various reference solvents, high field (W-band, 94 GHz) EPR
spectroscopy with a modulation amplitude of 0.5 mT and a
power of 0.5 µW at cryogenic temperature (−193 °C) were per-
formed on a Elexsys E680 EPR spectrometer equipped with a
Teraflex EN600-1021H probe head (both Bruker Biospin,
Karlsruhe, Germany). The temperature was adjusted by an
ITC503 temperature controller (Oxford Instruments,
Oxfordshire, United Kingdom). Samples were filled into quartz
glass capillaries with 0.87 mm/0.7 mm (OD/ID) (VitroCom Inc.
Mountain Lakes, NJ, USA). The magnetic field was calibrated
by using N@C60 for each measurement.51 All X- and W-band
EPR spectra were analyzed with Easyspin,52 a toolbox for
Matlab (The MathWorks Inc., Natick, MA, USA).
Penetration of DXM into excised human skin
Cutaneous absorption of DXM into human skin was studied
using abdominal human skin obtained from plastic surgeries
(with informed consent; ethics vote from the Charité Mitte,
Berlin, EA1/081/13) according validated protocols.53 After sur-
gical removal, the subcutaneous layer of the skin was removed,
the skin was washed with PBS and kept in a freezer (−20 °C,
<6 months). During the experiment, the defrosted skin was
placed in cell culture well inserts with a growth area of 4.2 cm2
(BD Biosciences, Heidelberg, Germany). Commercially avail-
able DXM LAW® cream and DXM loaded tNGs (3 wt%) were
applied on the skin surface (5 µg cm−2 DXM). To mimic temp-
erature gradient within the skin, temperature was increased
from 32 to 37 °C in the first 3 h and held there for the remain-
ing incubation. The donor compartment under cell culture
inserts was filled with PBS. After incubation, surplus material
was carefully removed and the skin was stripped twice with
adhesive tape. In order to quantify the DXM amount in the
skin layers, epidermis and dermis were heat separated (1 min
in 60 °C hot water) and dermis was horizontally cut into 8 sec-
tions á 50 μm at 24 °C using a freeze microtome (Frigocut 230
2800N, Leica Microsystems Holding GmbH, Bensheim,
Germany). Epidermis and dermis skin slices were subjected to
5 freeze–thaw cycles. Following the addition of 40 pmol DXM-
d4 as internal standard, samples were extracted 3 times with
500 μL ethyl acetate. Combined extracts were exsiccated by
vacuum rotation and the dried residues were dissolved in
200 μL acetonitrile. DXM concentrations were quantified by
LC-MS/MS as described previously.54
Generation of skin equivalents and treatment with DXM
loaded cream and nanogels
Normal (FLG+) and filaggrin-deficient (FLG−) skin equivalents
were generated according to previously published pro-
cedures.55 Primary human keratinocytes and fibroblasts were
isolated from juvenile foreskin, acquired from circumcision
surgeries (ethics vote from the Charité Mitte, Berlin, EA1/081/
13). To induce gene knockdown, keratinocytes were transfected
(HiPerFect®; Qiagen, Hilden, Germany) with FLG specific
siRNA (Sequence: CAGCUCCAGACAAUCAGGCACUCAU;
NM_002016, Invitrogen, Darmstadt, Germany). Primary
human fibroblasts, FCS Superior (Merck Millipore, Darmstadt,
Germany) and bovine collagen I (PureCol; Advanced BioMatrix,
San Diego, USA) were brought to neutral pH and poured into
3D cell culture well inserts with a growth area of 4.2 cm2 (BD
Biosciences, Heidelberg, Germany). After 2 h at 37 °C, defined
cell culture medium was added and the system transferred to
an incubator with 5% CO2 and 95% humidity. After 2 h,
primary human keratinocytes (with or without filaggrin knock-
down) were added on top of the collagen matrix. After 24 h,
the skin equivalents were lifted to the air-liquid interface and
a diﬀerentiation medium was added. The equivalents were cul-
tivated for 14 d with media change every second day. Starting
at day 10, the culture media was supplemented with 15
ng mL−1 IL-4 and IL-13. At day 11 and day 13 skin models were
treated with DXM LAW® cream or loaded in tNGs (3 wt%) in a
dose of 2 µg cm−2 (4 µg cm−2 in total) and their respective
drug free vehicles. To mimic temperature gradient within the
skin, temperature was increased from 32 to 37 °C in the first
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3 h and held there for the remaining incubation. Carrier con-
centration within the aqueous solution was set at 5 mg mL−1.
To investigate the penetration of the tNGs, they were
labeled with the fluorescent dye IDCC and applied on the skin
models at the same carrier amount used above. For histo-
logical analysis, skin models were immediately frozen, and cut
into 8 µm vertical slices using a Leica CM 1510 S cryotome
(Leica Biosystems, Nussloch, Germany). Skin sections were
fixed with 4% formaldehyde, embedded in 4′,6-diamidin-2-
phenylindol (DAPI) antifading mounting medium afterwards
and analyzed under a fluorescence microscope (BZ-8000,
objectives 20×/0.75, zoom 10×, Plan-Apo, DIC N2, Keyence,
Neu-Isenburg, Germany).
Western blot
The epidermis was gently removed from the models and pro-
teins were extracted with radioimmunoprecipitation assay
(RIPA) buﬀer. Total protein concentrations were determined
using the Pierce® BCA Protein Assay Kit (Thermo Fisher
Scientific, Schwerte, Germany). Subsequently, samples (30 μg
protein) were boiled in standard SDS-PAGE sample buﬀer and
separated by 10% SDS polyacrylamide gel electrophoresis (Bio-
Rad, Munich, Germany). Gels were blotted onto nitrocellulose
membranes (Bio-Rad, Munich, Germany). After blocking with
5% skimmed-milk powder for 1 h at 37 °C, membranes were
incubated with primary antibodies at 4 °C overnight (rabbit
polyclonal to filaggrin 1 : 1000, rabbit polyclonal to involucrin
1 : 1000, rabbit polyclonal to TSLP 1 : 1000, mouse monoclonal
to β-actin 1 : 10 000). Blots were washed and incubated with
anti-rabbit horseradish-peroxidase-conjugated secondary anti-
body (Cell Signaling, Frankfurt/Main, Germany) for 1 h in a
dilution of 1 : 1000. Afterwards, blots were developed with
SignalFire™ ECL reagent (Cell Signaling, Frankfurt/Main,
Germany) and visualized by a PXi/PXi Touch gel imaging
system (Syngene, Cambridge, UK). Protein expression was semi
quantified by densitometry and normalized to β-actin levels
using ImageJ version 1.46r (National Institutes of Health,
Bethesda, USA). Potential oﬀ-target eﬀects on respective
protein expression levels due to siRNA transfection were
excluded previously by using skin models generated with
siRNA negative control.38
Results and discussion
Synthesis of thermoresponsive nanogels
The chemical ligation of βCD to the polymeric building blocks
requires its modification to allow eﬃcient coupling reactions.
The controlled and selective modification of βCD was per-
formed according to a protocol of Ng et al.56 by initial tosyla-
tion of one primary alcohol followed by the displacement with
sodium azide (Fig. 1a). The products were characterized by
means of 1H-NMR and IR spectroscopy to assure the modifi-
cation on a single hydroxide (C6) of the βCD. This functionali-
zation was selected to enable the decoration of polymers with
βCD-N3, since more than one functional group would possibly
cause to undesired crosslinking reactions. Following, the dPG-
(NH2)15% was reacted with BCN to enable the strain-promoted
alkyne–azide cycloaddition (SPAAC) reaction57 allowing the
facile and mild grafting of βCD-N3 on to the dPG surface
(Fig. 1b). Three diﬀerent conjugates were synthesized diﬀering
in the percentage of βCD units per dPG: 1%, 3%, and 5% of
the total hydroxyl groups of the dPG. The remaining alkynes
were left to react with the thermoresponsive polymer, during
nanogels synthesis. Interestingly, already at the lowest percen-
tage of βCD grafting, the water solubility of the dPG-(βCD)1%
dropped, appearing as a slightly turbid solution. Obviously,
the solubility decreased with increasing amount of βCD, result-
ing in a non-soluble conjugate for the dPG-(βCD)5%.
The nanogels were prepared by the thermonanoprecipitation
approach where the presynthesized polymeric precursors, i.e.
dPG-BCN and tPG-(N3)2, were dissolved in DMF and injected
into water at 45 °C, above the Tcp of the thermoresponsive poly-
mers. The crosslinking occurred via the strain-promoted
alkyne–azide cycloaddition (SPAAC) between the orthogonally
functionalized polymers. Two routes were exploited for the
introduction of βCD onto the nanogels (Fig. 2).
Route 1 follows the functionalization of the macro-cross-
linker (dPG) with the βCD prior to the nanogels synthesis.
Such approach would enable more controlled and quantitat-
ively precise introduction of the βCD on the formed nanogels.
Using this route however, no stable nanoparticles could be
obtained, most probably due to uncontrolled aggregation of
the dPG-(BCN)-(βCD) adduct resulting from its low water
solubility.
Nevertheless, stable βCD grafted thermoresponsive nano-
gels could be obtained using route 2 (Fig. 2). In this case dPG-
(BCN) was crosslinked with tPG-(N3)2 via thermonanoprecipita-
tion to form stable polymeric nanoparticles. In a second step
the excess of cyclooctyne moieties were quenched with βCD-N3
as both quenching and post-functionalization agent to form
the surface decorated nanogels. Depending on the functionali-
zation of dPG with -(BCN)5% or -(BCN)15% (Table 1) it could be
shown that the thermoresponsive behavior of the resulting
nanogel is influenced by the amount of tPG used for the cross-
linkage. As a result of the low functionalization percentage on
dPG-(BCN)5%, the weight ratio between the two macromolecu-
Fig. 1 Functionalization of the macromolecular precursors.
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lar precursors had to be adjusted accordingly to 47–62 wt% of
dPG-(BCN)5%, to ensure constant ratios between the functional
groups. However, in that case the synthesis resulted in nano-
particles with broad PDIs and no thermoresponsive behavior.
Therefore, a minimum amount of tPG is necessary for the
thermonanoprecipitation to occur, which should not fall
below 53 wt%.
Nevertheless, the increasing weight percentage (wt%) of
tPG in the nanogels formed with dPG-(BCN)15% result in
narrow PDI values and thermally triggered size reduction of
the nanoparticles, as analyzed by DLS. The narrow PDI values
for increasing wt% of tPG are most probably resulted by the
fact that the thermonanoprecipitation process is governed by
the phase transition of the tPG (from soluble below its tran-
sition temperature, and precipitated when the transition temp-
erature is crossed). Hence, its domination created the suitable
conditions for the formation of the uniform precursor par-
ticles. Interestingly, the introduction of βCD to the tNGs had
only a minor influence on their Tcp (Fig. 3a). The Tcp of
tNG_tPG was measured to occur at 33.9 °C while decreasing to
32.3 °C for tNG_tPG_βCD. This tendency can be attributed to
the rather hydrophobic nature of βCD, while the minor influ-
ence arises from the fact the surface decoration of the tNGs
was achieved by utilizing the multifunctionality of the cross-
linker dPG, without modifying the thermoresponsive polymer
itself. Moreover, this approach enables the decoration of the
nanogels surface with the desired functionality: i.e. with IDCC-N3
for fluorescent labelling or azidopropanol for quenching of the
unreacted alkynes. TEM and AFM measurments of
tNG_tPG_βCD confirmed the presence of spherical particles in
the sizes of 230 ± 70 nm (Fig. 3b and c). The enlarged surface
visible in the microscopy images is caused by the flattening of
the dehydrated particles expressed by a height profile of 20.6 nm
by AFM. Furthermore, the ability of βCD to form an inclusion
complex with 8-anilinonaphthalene-1-sulfonic acid (ANS) was
employed to qualitatively characterize the tNG surface
decoration.58–61 ANS is a known guest molecule for the cyclic
sugar, which complexation leads to gain in its fluoresce intensity.
Thus, tNG_tPG_βCD were added to an aqueous solution of ANS
which resulted in increase of the fluorescent signal until a satur-
ation point (Fig. S1†), suggesting successful grafting of βCD.
Fig. 2 Synthesis of β-CD grafted thermoresponsive nanogels.




PDIbBCN –N3 (dPG) 25 °C 45 °C
dPG-BCN5% 3 1 62 200 — 0.405
2 1 53 140 — 0.472
1.5 1 47 120 — 0.500
dPG-BCN15% 3 1 37 70 60 0.170
2 1 28 80 62 0.200
1.5 1 23 75 63 0.108
a Functional group (FG) feed ratio. b Size and polydispersity index (PDI)
by DLS in water at 25 °C. Measurements were performed in triplicates;
intensity average mean value presented.
Fig. 3 Characterization of tNG_tPG_βCD. (a) Transmission vs. temperature measured by UV-Vis at 500 nm in PBS (1 mg mL−1), compared to
tNG_tPG (b) TEM, and (c) AFM.
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The encapsulation of the DXM in the tNGs could be
achieved by sonication of the tNG/DXM suspension, followed
by filtration of the excess of drug. The maximum encapsula-
tion capacity reached for tNG_tPG was 5.8 ± 0.2 wt% as
reported elsewhere.36 The introduction of βCD to the tNG
scaﬀold did not improve the encapsulation capacity of DXM,
but rather decreased it to 4.1 ± 0.2 wt%. This can be attributed
to aggregation patterns that the βCD can induce to the tNGs,
while the entrapment of DXM in the hydrophobic pocket of
βCD is not expected to have a large impact on the encapsula-
tion eﬃciencies. Both tNGs with the encapsulated drug were
incubated below (25 °C) and above (37 °C) their Tcp to study
the in vitro release kinetics of DXM (Fig. 4). While a slight
increase in the released DXM amount was observed for both
tNGs incubated at 37 °C, this could not be attributed to temp-
erature triggered release. In line with previous reports, the
release of a low Mw drug could not be triggered by the confor-
mational change of the tNGs but occurred by slow diﬀusion of
the drug from the polymer matrix. Moreover, the presence of
βCD on the tNG surface, did not influence the release kinetics
of the drug incubated below and above the Tcp.
EPR study on the association of DXM to βCD
EPR investigations pointed out diﬀerent environments for
DXM-PCA loaded to the tNGs with and without βCD, taking
into account DXM-PCA dissolved in various reference solvents.
The EPR spectrum of DXM-PCA in water is characterized by
three sharp lines of almost identical height (Fig. 5). For the
aqueous dispersion of the tNG_tPG loaded with the spin
labeled drug the spectral shape is comparable, representing a
freely tumbling molecule in solution. For DXM-PCA in DMSO
already a slight reduction of the line intensity at 336 mT can
be noticed owing to the higher viscosity of this solvent, thus
leading to lower mobility.
The EPR spectrum of DXM-PCA loaded to tNG_tPG_βCD
diﬀers remarkably recognizable by spectral broadening of the
high-field line (at 336 mT) in comparison to tNG_tPG (DMSO
and water) (Fig. 5). By comparison, the EPR spectra of
DXM-PCA loaded to tNG_tPG_βCD and in an aqueous solution
of βCD (Fig. 5) illustrate that the cyclic oligosaccharide seems
to be responsible for the restricted mobility of DXM-PCA.
In general, the mobility of a spin label is encoded into the
spectral shape of an EPR spectrum as incomplete time-aver-
aging over the anisotropic magnetic interactions by the tum-
bling motion of the molecule.62 A measure for the mobility is
the rotational correlation time tcorr, which can be deduced by
simulation of the EPR spectrum. For a consistent simulation
of the EPR spectra at r.t., the magnetic parameters (g- and 14N
hyperfine matrices) should be measured independently.
Therefore EPR spectra at 94 GHz were acquired, from which by
simulation the g-matrix and the 14N hyperfine coupling could
be estimated (see Table 2, Fig. S2, and Table S1†).
The obtained magnetic parameters (gxx, and Azz, see
Table 2) illustrate the polarity of DXM-PCA’s environment
loaded to the various tNG dispersions and dissolved in
diﬀerent reference solutions. The gxx value and the Azz com-
ponent are known to be sensitive to the polarity of the environ-
ment.49,50 DXM-PCA loaded to tNG_tPG shows a similar EPR
Fig. 4 Cumulative release of DXM from tNG_tPG at 25 °C (black
circles) and 37 °C (hollow circles) and from tNG_tPG_βCD at 25 °C
(black squares) and 37 °C (hollow squares).
Fig. 5 X-band EPR spectra of DXM-PCA subjected to tNG_tPG,
tNG_tPG_βCD, DMSO, and water at 25 °C, normalized to the maximum
height of the middle peak. Simulations are shown in dashed lines.
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spectrum as in water (Table 2), indicating a high mobility of
DXM-PCA in this dispersion. A little tendency towards a more
apolar environment for tNG_tPG is given, recognizable by the
slight upshift of gxx and correspondingly downshift of Azz
(Table 2). For DXM-PCA loaded to tNG_tPG_βCD and dissolved
in the aqueous βCD solution the change is noticeably higher
reflecting a more apolar environment. Interestingly, for both
βCD containing solutions the same magnetic as well as mobi-
lity parameters were obtained indicating a similar environ-
ment for DXM-PCA.
Comparing the parameters obtained from EPR the follow-
ing conclusions can be drawn: (a) for the tNG_tPG_βCD dis-
persion as well as the βCD solution DXM-PCA is located in a
more apolar environment compared to the tNG_tPG dis-
persion, (b) the rotational correlation time reports for the
same partial immobilization of the drug in these βCD contain-
ing solutions. Taking these two facts together, the most prob-
able location of DXM-PCA is within the hydrophobic pocket of
βCD, leading to a more apolar environment and hindered
rotation compared to the tNG_tPG dispersion and aqueous
solution.
Dexamethasone delivery into human skin ex vivo
Topical corticosteroid administration, such as DXM cream, is a
benchmark therapy for inflammatory skin diseases such as
AD.64 To investigate the delivery eﬃcacy by the tNGs, 3 wt%
DXM was incorporated into the nanogels. In line with previous
studies,65 distinct penetration of 0.2 µg cm−2 DXM into the
epidermis was found by topical application of the LAW®
cream for 6 h (Fig. 6a). Loading DXM in tNGs_tPG had no
further influence on the delivery into the epidermis, but led to
a distinct increase in drug amounts in the dermis. These
results may be explained by recent findings, where the
tNG_tPG act as penetration enhancers by increasing the
hydration of the SC with consequent perturbation of the lipids
and proteins organization.34 Interestingly, βCD functionalized
tNGs significantly increased the amounts of DXM in both skin
layers, when compared to the standard cream treatment
(∼2.5 fold in epidermis; ∼30 fold in dermis). These results
demonstrated the ability of βCD to act as a topical penetration
enhancer when used as an integral part of a polymeric carrier
system. The direct interaction between DXM and βCD shown
by the EPR data, suggests enhanced penetration of DXM due
to its increased solubilization, directly influencing the avail-
ability of the drug. Along with that, the coordination complex
did not retain the drug in the carrier, but allowed its diﬀusion
into the deeper skin layers faster than the control groups
(Fig. 6a). Notably, the temperature ramp from 32 °C–37 °C was
chosen to simulate the natural thermal gradient of human
skin: the outermost layer having a surface temperature of
32 °C which gradually increases with SC depth ultimately
reaching 37 °C in the viable epidermis.35
After 24 h, no distinct variation of DXM amounts were
found in skin samples treated with tNG_tPG_βCD compared to
the short treatment, however, cream treatment and tNG_tPG
almost doubled the DXM amount (Fig. 6b). Nevertheless, the
βCD decorated tNGs retained DXM concentration in both skin
layers, dominating over the control groups after 24 h of incu-
bation, with a recovered drug concentration of ∼1.2 µg cm−2,
while the rest removed from skin surface by tape stripping or
discarded from the acceptor compartment. This might suggest
the ability of tNG_tPG_βCD to act as drug reservoirs, maintain-
ing DXM concentration over longer periods of time. Data-
based modeling of DXM penetration depth based on its
diﬀusivity and free energy profiles, has previously shown the
Table 2 Magnetic parameters of DXM-PCA encapsulated in various
tNGs and dissolved in diﬀerent reference solvents (βCD aqueous solu-
tion, DMSO, water) at −193 °C
Sample gxx Azz (MHz) tcorr (25 °C)
tNG_tPG + DXM-PCA 2.00840(3) 101(1) 80 ps
tNG_tPG_βCD + DXM-PCA 2.00870(5) 99(1) 400 ps
βCD + DXM-PCA 2.00870(5) 99(1) 400 ps
DXM-PCA@Water63 2.00810(2) 104(1) 80 ps
DXM-PCA@DMSO63 2.00864(4) 100(1) 140 ps
Fig. 6 DXM penetration into human skin assessed by LC-MS/MS. DXM amount [µg cm−2] in human epidermis and dermis after topical exposure for
6 h (a) and 24 h (b) incorporated in a commercially available LAW® cream or tNGs. Temperature was increased from 32 to 37 °C in the ﬁrst 3 h and
held there for the remaining incubation. Statistical diﬀerences were assessed by one-way ANOVA and Dunett post analyses compared to the LAW®
cream treatment (mean ± SEM; n = 3).
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considerably moderate drug diﬀusion through the SC while
reaching a distinct free energy barrier (high solubility) in the
viable epidermis.66 Thus, the penetration profile of DXM with
the aid of tNG_tPG_βCD, might alternatively suggest an
increased diﬀusivity through the SC reaching a dynamic equili-
brium state of DXM concentration in the viable epidermis and
the dermis layers.
Therapeutic eﬃcacy of DXM loaded βCD functionalized
thermoresponsive nanogels
To evaluate the pharmacological eﬃcacy of delivered DXM we
treated previously established skin equivalent exhibiting
characteristics of AD in vitro.38 These characteristics were
described by altered skin histology, changes in the expression
of epidermal barrier proteins and defects in the cutaneous
innate immune response. Significant changes in the
expression of the cytokine TSLP, which is considered a key
player in AD pathogenesis,67 were confirmed in the present
study and used as a pharmacological read out parameter for
the anti-inflammatory treatment. Compared to untreated,
normal (FLG+) skin equivalents, a distinct upregulation of
TSLP was observed in diseased skin equivalents, which exhibit-
ing a deficiency of filaggrin (FLG−) and a simultaneous Th2
triggered inflammation (IL-4/IL-13) (Fig. 7a and Hönzke
et al.).38 TSLP primes diﬀerentiation of naïve proliferative T
cells into Th2 cells by either direct activation68 or indirect acti-
vation trough dendritic cells.69 These activation of immune
cells is followed by secretion of high levels of other pro-inflam-
matory cytokines such as TNFα.69 Glucocorticoids such as
DXM have the anti-inflammatory potency to suppress the acti-
vation of the immune response by modulating the activation
of various transcription factors within the inflamed tissue.70
Interestingly for TSLP it is known, that the expression within
keratinocytes is hampered by glucocorticoids trough binding
to a negative glucocorticoid response element.71 In line with
these findings we found decreased TSLP levels in the
DXM treated skin equivalents compared to the untreated
FLG−IL-4/IL-13 equivalent (Fig. 7a). In accordance with the
ex vivo penetration data (Fig. 6), we found a significant down-
regulation of the inflammation, exclusively in the skin equiva-
lents, which were treated with the DXM loaded tNG_tPG_βCD.
These findings further demonstrated the downregulating
eﬀect of DXM on the expression of TSLP, as previously shown
in a mouse model of AD.72 Furthermore, it must be noted that
both tNGs did not overcome the SC of the skin equivalents
indicating that the observed eﬀects result from enhanced DXM
delivery (Fig. 7b and c). Notably, human-based skin disease
models were specifically chosen, since inter-species related
eﬀects, which occur for example with mice, are avoided.73
Moreover, their applicability for assessing drug eﬀects has
been repeatedly demonstrated qualifying them as valuable
alternatives to animal studies.74–77
Conclusions
To conclude, we present here a joint approach for the topical
delivery of hydrophobic drugs by utilizing polymeric nanopar-
ticulate delivery systems combined with conventional pene-
tration enhancers. The tNGs were decorated with βCD units by
strain promoted click chemistry of the orthogonally functiona-
lized precursors. The chosen synthetic pathway of post
functionalization allowed to overcome aggregations and low
solubility of the polymeric precursors caused by the rather
hydrophobic βCD. Similar approach was used for the decora-
tion of the tNGs with a fluorescent dye or quenching of the
unreacted moieties. DXM could be encapsulated within the
tNGs while interestingly, βCD did not change the properties of
the carrier nor the in vitro release kinetics of DXM. EPR
studied could explicitly locate the encapsulated drug within
the hydrophobic cavity of βCD, while retaining its mobility in
the bare tNGs. Nevertheless, when applied on excised human
skin, tNG_tPG_βCD were superior in their ability to deliver
DXM to the viable epidermis and the dermis compared to the
unfunctionalized tNGs, but more importantly, to a commercial
DXM formulation. This eﬀect was further pronounced when
the βCD decorated tNGs were the only ones able to down regu-
late the TSLP expression in the treatment of inflammatory skin
equivalents. Exploiting nanocarriers coupled to topical pene-
tration enhancers presents a promising strategy for the topical
Fig. 7 (a) Western blots and relative protein expression of TSLP semi-
quantiﬁed via densitometry of untreated normal (FLG+) and ﬁlaggrin
knockdown (FLG−) (untreated and IL-4/IL-13 supplemented) skin
equivalents. Skin equivalents were topically treated at day 11 and day 13
with DXM loaded onto LAW® cream, tNG_tPG or tNG_tPG_βCD.
Temperature was increased from 32 to 37 °C in the ﬁrst 3 h and held
there for the remaining incubation. Statistical diﬀerences were calcu-
lated by Student‘s t-test compared to FLG−IL-4/IL-13 (** = p ≤ 0.01) or
compared to FLG+ (+ = p ≤ 0.05, Mean ± SEM; n = 5). (b, c)
Representative ﬂuorescence imaging of ﬂuorescent labeled tPG (red) (b)
and tPG_βCD (c) nanogels in FLG−IL-4/IL-13 skin equivalents. The skin
equivalent sections were counterstained with DAPI (blue). Dashed lines
indicate the SC, viable epidermis (VE), dermis (DE). Scale bar = 50 µm.
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delivery of various hydrophobic drugs while ensuring the
retention of the delivery system in the SC, avoiding potential
irritation.
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